Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
5.65
-0.01 (-0.18%)
Jan 16, 2026, 11:33 AM EST - Market open
Solid Biosciences Employees
Solid Biosciences had 100 employees as of December 31, 2024. The number of employees increased by 12 or 13.64% compared to the previous year.
Employees
100
Change (1Y)
12
Growth (1Y)
13.64%
Revenue / Employee
n/a
Profits / Employee
-$1,671,350
Market Cap
440.19M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100 | 12 | 13.64% |
| Dec 31, 2023 | 88 | 1 | 1.15% |
| Dec 31, 2022 | 87 | -17 | -16.35% |
| Dec 31, 2021 | 104 | 34 | 48.57% |
| Dec 31, 2020 | 70 | -51 | -42.15% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLDB News
- 2 days ago - Solid Biosciences Inc. (SLDB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 days ago - Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 - GlobeNewsWire
- 3 days ago - Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia - GlobeNewsWire
- 4 days ago - Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia - GlobeNewsWire
- 10 days ago - Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 10 days ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services - GlobeNewsWire
- 5 weeks ago - Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum - GlobeNewsWire